Progyny price target raised to $35 from $30 at BTIG

Core Viewpoint - BTIG has raised the price target for Progyny (PGNY) to $35 from $30 while maintaining a Buy rating, following insights from the JP Morgan Healthcare Conference [1] Group 1: Financial Performance - Progyny is expected to report Q4 revenue, net income, and adjusted EBITDA slightly above previous guidance due to favorable member engagement tracking [1] - The company is experiencing strong demand, new client acquisitions, and an increase in member additions, indicating robust growth [1] Group 2: Market Position - Progyny continues to strengthen its industry-leading position in the fertility and family building sector [1]